Company Performance - Biorestorative Therapies reported revenues of $0.04 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 16.67% and up from $0.03 million year-over-year [2] - The company posted a quarterly loss of $0.53 per share, compared to the Zacks Consensus Estimate of a loss of $0.51, and a loss of $1.53 per share a year ago [8] - Biorestorative Therapies has surpassed consensus EPS estimates three times over the last four quarters [9] Stock Performance - Biorestorative Therapies shares have declined approximately 32.8% since the beginning of the year, while the S&P 500 has gained 12.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $0.03 million, and for the current fiscal year, it is -$1.96 on revenues of $0.12 million [5] Industry Context - The Medical - Biomedical and Genetics industry, to which Biorestorative Therapies belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook [13] - The performance of Biorestorative Therapies may be influenced by the overall industry outlook, as top-ranked industries tend to outperform lower-ranked ones significantly [13]
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates